Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDORE: Switch to Doravirine for INSTI-Associated Weight Gain
NCT05477407Completed
- Sponsor
- Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by Centre de Recherches et d'Études sur la Pathologie Tropicale et le Sida. Primary endpoints: Measure the phenotype and alterations in adipose tissue to assess the impact of this weight gain at 48 weeks, Measure of markers of white adipose tissue, brown/beige adipose tissue, to assess changes in gene expression at 48 weeks and 2 more. Started Oct 2022; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05477407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477407.